Enhancing Anti-Tumor Activity of Sorafenib Mesoporous Silica Nanomatrix in Metastatic Breast Tumor and Hepatocellular Carcinoma via the Co-Administration with Flufenamic Acid
| Autor: | Yang Guo, Shuang Zhang, Jing-Ru Wang, Mei-Qi Xu, Xiao-Chuan Duan, Man Liu, Xuan Zhang, Hui Li, Zhuo-Yue Li, Ai Liao, Zhen-Han Feng, Yi-Fan Yin, Shuai-Qiang Zhang, Guang-Xue Wang, Shu-Min Wang |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
Male
Cell Pharmaceutical Science 02 engineering and technology 01 natural sciences Cell Movement International Journal of Nanomedicine Antineoplastic Combined Chemotherapy Protocols sorafenib mesoporous silica nanomatrix Drug Discovery Original Research Mice Inbred BALB C Chemistry 4T1/luc Anti-Inflammatory Agents Non-Steroidal Liver Neoplasms AKR1C1 Cell migration Hep G2 Cells General Medicine Sorafenib AKR1C3 Silicon Dioxide 021001 nanoscience & nanotechnology medicine.anatomical_structure Hepatocellular carcinoma Female lipids (amino acids peptides and proteins) PGE2 medicine.symptom 0210 nano-technology hormones hormone substitutes and hormone antagonists medicine.drug HepG2 Carcinoma Hepatocellular Biophysics Mice Nude Breast Neoplasms Bioengineering Inflammation 010402 general chemistry Dinoprostone MSNM@SFN Biomaterials flufenamic acid In vivo Cell Line Tumor medicine Animals Humans 20-Hydroxysteroid Dehydrogenases Organic Chemistry Aldo-Keto Reductase Family 1 Member C3 medicine.disease Xenograft Model Antitumor Assays digestive system diseases In vitro Nanostructures 0104 chemical sciences body regions Flufenamic acid Cancer research FFA |
| Zdroj: | International Journal of Nanomedicine |
| ISSN: | 1178-2013 |
| Popis: | Zhuo-Yue Li,1,2 Yi-Fan Yin,1,2 Yang Guo,1,2 Hui Li,1,2 Mei-Qi Xu,1,2 Man Liu,1,2 Jing-Ru Wang,1,2 Zhen-Han Feng,1,2 Xiao-Chuan Duan,1,2 Shuang Zhang,1,2 Shuai-Qiang Zhang,1,2 Guang-Xue Wang,2 Ai Liao,2 Shu-Min Wang,3 Xuan Zhang1,2 1Beijing Key Laboratory of Molecular Pharmaceutics and New Drug Delivery Systems, School of Pharmaceutical Sciences, Peking University, Beijing 100191, People’s Republic of China; 2Department of Pharmaceutics, School of Pharmaceutical Sciences, Peking University, Beijing 100191, People’s Republic of China; 3Department of Ultrasound, Peking University Third Hospital, Peking University, Beijing 100191, People’s Republic of ChinaCorrespondence: Xuan ZhangDepartment of Pharmaceutics, School of Pharmaceutical Sciences, Peking University, Xueyuan Road 38, Beijing 100191, People’s Republic of ChinaTel/Fax +86-10-82805765Email xuanzhang@bjmu.edu.cnShu-Min WangDepartment of Ultrasound, Peking University Third Hospital, Peking University, Xueyuan Road 38, Beijing 100191, People’s Republic of ChinaEmail shuminwang2014@163.comIntroduction: Because tumor-associated inflammation is a hallmark of cancer treatment, in the present study, sorafenib mesoporous silica nanomatrix (MSNM@SFN) co-administrated with flufenamic acid (FFA, a non-steroidal anti–inflammatory drug (NSAID)) was investigated to enhance the anti-tumor activity of MSNM@SFN.Methods: Metastatic breast tumor 4T1/luc cells and hepatocellular carcinoma HepG2 cells were selected as cell models. The effects of FFA in vitro on cell migration, PGE2 secretion, and AKR1C1 and AKR1C3 levels in 4T1/luc and HepG2 cells were investigated. The in vivo anti-tumor activity of MSNM@SFN co-administrating with FFA (MSNM@SFN+FFA) was evaluated in a 4T1/luc metastatic tumor model, HepG2 tumor-bearing nude mice model, and HepG2 orthotopic tumor-bearing nude mice model, respectively.Results: The results indicated that FFA could markedly decrease cell migration, PGE2 secretion, and AKR1C1 and AKR1C3 levels in both 4T1/luc and HepG2 cells. The enhanced anti-tumor activity of MSNM@SFN+FFA compared with that of MSNM@SFN was confirmed in the 4T1/luc metastatic tumor model, HepG2 tumor-bearing nude mice model, and HepG2 orthotopic tumor-bearing nude mice model in vivo, respectively.Discussion: MSNM@SFN co-administrating with FFA (MSNM@SFN+FFA) developed in this study is an alternative strategy for improving the therapeutic efficacy of MSNM@SFN via co-administration with NSAIDs.Keywords: sorafenib mesoporous silica nanomatrix, MSNM@SFN, flufenamic acid, FFA, PGE2, AKR1C1, AKR1C3, 4T1/luc, HepG2 |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|